Investigate Absorption, Metabolism, Excretion, and Mass Balance of Pacritinib
Status:
Completed
Trial end date:
2014-10-01
Target enrollment:
Participant gender:
Summary
This study is an open-label, absorption, metabolism, excretion, and mass balance study of 400
mg [14C]pacritinib (containing 100 μCi radioactivity) administered orally as a single dose to
6 healthy male subjects following at least a 10-hour fast (not including water) on Day 1.